-
1
-
-
37449029464
-
Gastroenteropancreatic neuroendocrine tumours
-
Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61-72.
-
(2008)
Lancet Oncol
, vol.9
, pp. 61-72
-
-
Modlin, I.M.1
Oberg, K.2
Chung, D.C.3
-
2
-
-
69749113601
-
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification
-
Klöppel G, Couvelard A, Perren A, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology. 2009;90:162-166.
-
(2009)
Neuroendocrinology
, vol.90
, pp. 162-166
-
-
Klöppel, G.1
Couvelard, A.2
Perren, A.3
-
4
-
-
84873375319
-
Systemic therapeutic options for carcinoid
-
Pavel M, Kidd M, Modlin I. Systemic therapeutic options for carcinoid. Semin Oncol. 2013;40:84-99.
-
(2013)
Semin Oncol
, vol.40
, pp. 84-99
-
-
Pavel, M.1
Kidd, M.2
Modlin, I.3
-
5
-
-
84876103467
-
Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs)
-
Kanakis G, Kaltsas G. Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Best Pract Res Clin Gastroenterol. 2012;26:791-802.
-
(2012)
Best Pract Res Clin Gastroenterol
, vol.26
, pp. 791-802
-
-
Kanakis, G.1
Kaltsas, G.2
-
6
-
-
84881558928
-
Improving the diagnosis and management of neuroendocrine tumors: Utilizing new advances in biomarker and molecular imaging science
-
Giandomenico V, Modlin IM, Pontén F, et al. Improving the diagnosis and management of neuroendocrine tumors: Utilizing new advances in biomarker and molecular imaging science. Neuroendocrinology. 2013;98:16-30.
-
(2013)
Neuroendocrinology
, vol.98
, pp. 16-30
-
-
Giandomenico, V.1
Modlin, I.M.2
Pontén, F.3
-
7
-
-
84871612736
-
Therapeutic monitoring of gastroenteropancreatic neuroendocrine tumors: The challenges ahead
-
Sundin A, Rockall A. Therapeutic monitoring of gastroenteropancreatic neuroendocrine tumors: The challenges ahead. Neuroendocrinology. 2012;96:261-271.
-
(2012)
Neuroendocrinology
, vol.96
, pp. 261-271
-
-
Sundin, A.1
Rockall, A.2
-
8
-
-
84857815160
-
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: Well-differentiated pancreatic non-functioning tumors
-
Falconi M, Bartsch DK, Eriksson B, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: Well-differentiated pancreatic non-functioning tumors. Neuroendocrinology. 2012;95:120-134.
-
(2012)
Neuroendocrinology
, vol.95
, pp. 120-134
-
-
Falconi, M.1
Bartsch, D.K.2
Eriksson, B.3
-
9
-
-
84938539612
-
The future of nuclear medicine imaging of neuroendocrine tumors: On a clear day one might see forever
-
Bodei L, Kidd M, Prasad V, Baum RP, Drozdov I, Modlin IM. The future of nuclear medicine imaging of neuroendocrine tumors: On a clear day one might see forever. Eur J Nucl Med Mol Imaging. 2014; 41(12):2189-2193.
-
(2014)
Eur J Nucl Med Mol Imaging
, vol.41
, Issue.12
, pp. 2189-2193
-
-
Bodei, L.1
Kidd, M.2
Prasad, V.3
Baum, R.P.4
Drozdov, I.5
Modlin, I.M.6
-
10
-
-
84922930634
-
Neuroendocrine tumor biomarkers: Current status and perspectives
-
Modlin IM, Oberg K, Taylor A, Drozdov I, Bodei L, Kidd M. Neuroendocrine tumor biomarkers: Current status and perspectives. Neuroendocrinology. 2014;100:265-277.
-
(2014)
Neuroendocrinology
, vol.100
, pp. 265-277
-
-
Modlin, I.M.1
Oberg, K.2
Taylor, A.3
Drozdov, I.4
Bodei, L.5
Kidd, M.6
-
11
-
-
84867413693
-
Neuroendocrine tumor disease: An evolving landscape
-
Frilling A, Akerström G, Falconi M, et al. Neuroendocrine tumor disease: An evolving landscape. Endocr Relat Cancer. 2012;19: R163-R185.
-
(2012)
Endocr Relat Cancer
, vol.19
, pp. R163-R185
-
-
Frilling, A.1
Akerström, G.2
Falconi, M.3
-
12
-
-
77956342399
-
Chromogranin A-biological function and clinical utility in neuro endocrine tumor disease
-
Modlin IM, Gustafsson BI,MossSF, PavelM,Tsolakis AV, KiddM. Chromogranin A-biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol. 2010;17:2427-2443.
-
(2010)
Ann Surg Oncol
, vol.17
, pp. 2427-2443
-
-
Modlin, I.M.1
Gustafsson, B.I.2
Moss, S.F.3
Pave, L.M.4
Tsolakis, A.V.5
Kidd, M.6
-
13
-
-
84857852641
-
Limitations of Chromogranin A in clinical practice
-
Marotta V, Nuzzo V, Ferrara T, et al. Limitations of Chromogranin A in clinical practice. Biomarkers. 2012;17:186-191.
-
(2012)
Biomarkers
, vol.17
, pp. 186-191
-
-
Marotta, V.1
Nuzzo, V.2
Ferrara, T.3
-
14
-
-
79952308016
-
Future directions in the treatment of neuroendocrine tumors: Consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting
-
Kulke MH, Siu LL, Tepper JE, et al. Future directions in the treatment of neuroendocrine tumors: Consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol. 2011;29:934-943.
-
(2011)
J Clin Oncol
, vol.29
, pp. 934-943
-
-
Kulke, M.H.1
Siu, L.L.2
Tepper, J.E.3
-
15
-
-
67349181854
-
Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors
-
Welin S, Stridsberg M, Cunningham J, et al. Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology. 2009; 89:302-307.
-
(2009)
Neuroendocrinology
, vol.89
, pp. 302-307
-
-
Welin, S.1
Stridsberg, M.2
Cunningham, J.3
-
16
-
-
84940109492
-
Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status
-
Kidd M, Drozdov I, Modlin I. Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status. Endocr Relat Cancer. 2015;22(4):561-575.
-
(2015)
Endocr Relat Cancer
, vol.22
, Issue.4
, pp. 561-575
-
-
Kidd, M.1
Drozdov, I.2
Modlin, I.3
-
17
-
-
84905994529
-
A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection
-
Modlin IM, Drozdov I, Alaimo D, et al. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection. Endocr Relat Cancer. 2014;21:615-628.
-
(2014)
Endocr Relat Cancer
, vol.21
, pp. 615-628
-
-
Modlin, I.M.1
Drozdov, I.2
Alaimo, D.3
-
18
-
-
0032883399
-
The interpretation of diagnostic tests
-
Shapiro DE. The interpretation of diagnostic tests. Stat Methods Med Res. 1999;8:113-134.
-
(1999)
Stat Methods Med Res
, vol.8
, pp. 113-134
-
-
Shapiro, D.E.1
-
19
-
-
0038004636
-
Clinical biomarkers in drug discovery and development
-
Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov. 2003;2:566-580.
-
(2003)
Nat Rev Drug Discov
, vol.2
, pp. 566-580
-
-
Frank, R.1
Hargreaves, R.2
-
20
-
-
84904253184
-
Lanreotide in metastatic enteropancreatic neuroendocrine tumors
-
Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.NEngl J Med. 2014;371: 224-233.
-
(2014)
N Engl J Med
, vol.371
, pp. 224-233
-
-
Caplin, M.E.1
Pavel, M.2
Ćwikła, J.B.3
-
21
-
-
70350442637
-
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group
-
Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J Clin Oncol 2009;27:4656-4663.
-
(2009)
J Clin Oncol
, vol.27
, pp. 4656-4663
-
-
Rinke, A.1
Muller, H.H.2
Schade-Brittinger, C.3
-
22
-
-
46749090507
-
Initial direct comparison of 99mTc-TOC and 99mTc-TATE in identifying sites of disease in patients with proven GEP NETs
-
Ćwikła JB, Mikolajczak R, Pawlak D, et al. Initial direct comparison of 99mTc-TOC and 99mTc-TATE in identifying sites of disease in patients with proven GEP NETs. J Nucl Med. 2008;49:1060-1065.
-
(2008)
J Nucl Med
, vol.49
, pp. 1060-1065
-
-
Ćwikła, J.B.1
Mikolajczak, R.2
Pawlak, D.3
-
23
-
-
77449132297
-
Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
-
Kwekkeboom DJ, Kam BL, van Essen M, et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2010;17:R53-R73.
-
(2010)
Endocr Relat Cancer
, vol.17
, pp. R53-R73
-
-
Kwekkeboom, D.J.1
Kam, B.L.2
Van Essen, M.3
-
24
-
-
84860651877
-
The clinical value of MRIusing single-shot echoplanarDWIto identify liver involvement in patients with advanced gastroenteropancreatic-neuroendocrine tumors (GEP-NETs), compared to FSE T2 and FFE T1 weighted image after i.v. Gd-EOB-DTPA contrast enhancement
-
Sankowski AJ, Ćwikła JB, Nowicki ML, et al. The clinical value of MRIusing single-shot echoplanarDWIto identify liver involvement in patients with advanced gastroenteropancreatic-neuroendocrine tumors (GEP-NETs), compared to FSE T2 and FFE T1 weighted image after i.v. Gd-EOB-DTPA contrast enhancement. Med Sci Monit. 2012;18(5):MT33-MT40.
-
(2012)
Med Sci Monit
, vol.18
, Issue.5
, pp. MT33-MT40
-
-
Sankowski, A.J.1
Ćwikła, J.B.2
Nowicki, M.L.3
-
25
-
-
84877727939
-
The Identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood
-
Modlin I, Drozdov I, Kidd M. The Identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood. Plos One. 2013;e63364.
-
(2013)
Plos One
, pp. e63364
-
-
Modlin, I.1
Drozdov, I.2
Kidd, M.3
-
26
-
-
84896130878
-
Gut neuroendocrine tumor blood qPCR fingerprint assay: Characteristics and reproducibility
-
Modlin I, Drozdov I, Kidd M. Gut neuroendocrine tumor blood qPCR fingerprint assay: Characteristics and reproducibility. Clin Chem. 2014;52:419-429.
-
(2014)
Clin Chem
, vol.52
, pp. 419-429
-
-
Modlin, I.1
Drozdov, I.2
Kidd, M.3
-
27
-
-
0038476015
-
A comparison between three commercial kits for chromogranin A measurements
-
Stridsberg M, Eriksson B, Oberg K, Janson ET. A comparison between three commercial kits for chromogranin A measurements. J Endocrinol. 2003;177:337-341.
-
(2003)
J Endocrinol
, vol.177
, pp. 337-341
-
-
Stridsberg, M.1
Eriksson, B.2
Oberg, K.3
Janson, E.T.4
-
28
-
-
0028874025
-
Measurements of chromogranin A, chromogranin B (secretogranin I), chromograninC( secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours
-
Stridsberg M, Oberg K, Li Q, Engström U, Lundqvist G. Measurements of chromogranin A, chromogranin B (secretogranin I), chromograninC( secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol. 1995;144:49-59.
-
(1995)
J Endocrinol
, vol.144
, pp. 49-59
-
-
Stridsberg, M.1
Oberg, K.2
Li, Q.3
Engström, U.4
Lundqvist, G.5
-
30
-
-
0020083498
-
The meaning and use of the area under a receiver operating characteristic (ROC) curve
-
Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982; 143:29-36.
-
(1982)
Radiology
, vol.143
, pp. 29-36
-
-
Hanley, J.A.1
McNeil, B.J.2
-
31
-
-
0020524559
-
A method of comparing the areas under receiver operating characteristic curves derived from the same cases
-
Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839-843.
-
(1983)
Radiology
, vol.148
, pp. 839-843
-
-
Hanley, J.A.1
McNeil, B.J.2
-
32
-
-
84903604456
-
Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: State of the art
-
de Mestier L, Dromain C, d'Assignies G, et al. Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: State of the art. Endocr Relat Cancer. 2014;21:R105-R120.
-
(2014)
Endocr Relat Cancer
, vol.21
, pp. R105-R120
-
-
De Mestier, L.1
Dromain, C.2
D'Assignies, G.3
-
33
-
-
82155166331
-
Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors
-
Lindholm DP, Oberg K. Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors. Horm Metab Res. 2011;43(12):832-837.
-
(2011)
Horm Metab Res
, vol.43
, Issue.12
, pp. 832-837
-
-
Lindholm, D.P.1
Oberg, K.2
-
34
-
-
80054812132
-
Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours
-
Oberg K. Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2011;18 Suppl 1:S17-S25.
-
(2011)
Endocr Relat Cancer
, vol.18
, pp. S17-S25
-
-
Oberg, K.1
-
35
-
-
77956338644
-
Plasma chromogranin A response to octreotide test: Prognostic value for clinical outcome in endocrine digestive tumors
-
Massironi S, Conte D, Sciola V, et al. Plasma chromogranin A response to octreotide test: Prognostic value for clinical outcome in endocrine digestive tumors. Am J Gastroenterol. 2010;105:2072-2078.
-
(2010)
Am J Gastroenterol
, vol.105
, pp. 2072-2078
-
-
Massironi, S.1
Conte, D.2
Sciola, V.3
-
36
-
-
84922396916
-
Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms:Alarge series from a single institution
-
Massironi S, Rossi RE, Casazza G, et al. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms:Alarge series from a single institution. Neuroendocrinology. 2014;100:240-249.
-
(2014)
Neuroendocrinology
, vol.100
, pp. 240-249
-
-
Massironi, S.1
Rossi, R.E.2
Casazza, G.3
-
37
-
-
84871379143
-
Chromogranin A is a sensitive marker of progression or regression in ileo-cecal neuroendocrine tumors
-
Jensen KH, Hilsted L, Jensen C, Mynster T, Rehfeld JF, Knigge U. Chromogranin A is a sensitive marker of progression or regression in ileo-cecal neuroendocrine tumors. Scand J Gastroenterol. 2013; 48:70-77.
-
(2013)
Scand J Gastroenterol
, vol.48
, pp. 70-77
-
-
Jensen, K.H.1
Hilsted, L.2
Jensen, C.3
Mynster, T.4
Rehfeld, J.F.5
Knigge, U.6
-
38
-
-
84903614285
-
The 2010 WHO classification of digestive neuroendocrine neoplasms: A critical appraisal four years after its introduction
-
Rindi G, Petrone G, Inzani F. The 2010 WHO classification of digestive neuroendocrine neoplasms: A critical appraisal four years after its introduction. Endocr Pathol. 2014;25:186-192.
-
(2014)
Endocr Pathol
, vol.25
, pp. 186-192
-
-
Rindi, G.1
Petrone, G.2
Inzani, F.3
-
39
-
-
33845479732
-
Catecholamine-secreting metastatic carcinoid as differential diagnosis in pheochromocytoma: Clinical, laboratory, and imaging clues in the search for the lurking neuroendocrine tumor (NET)
-
Whitman HH 3rd, Fishman EK, Oberg K, Wildman JM, Long AL. Catecholamine-secreting metastatic carcinoid as differential diagnosis in pheochromocytoma: Clinical, laboratory, and imaging clues in the search for the lurking neuroendocrine tumor (NET). Ann N Y Acad Sci. 2006;1073:59-78.
-
(2006)
Ann N y Acad Sci
, vol.1073
, pp. 59-78
-
-
Whitman, H.H.1
Fishman, E.K.2
Oberg, K.3
Wildman, J.M.4
Long, A.L.5
|